Evidence map›Paper›PMID 34503991›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2021

Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases.

David S Goldstein, Genessis Castillo, Patti Sullivan, Yehonatan Sharabi

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases.Journal of clinical neurology (Seoul, Korea) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

David S GoldsteinAutonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, Maryland (D.G., G.C., P.S.); NIH Academy Enrichment Program, OD/NIH (G.C.); and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.) goldsteind@ninds.nih.gov.
Genessis CastilloAutonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, Maryland (D.G., G.C., P.S.); NIH Academy Enrichment Program, OD/NIH (G.C.); and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.).
Patti SullivanAutonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, Maryland (D.G., G.C., P.S.); NIH Academy Enrichment Program, OD/NIH (G.C.); and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.).
Yehonatan SharabiAutonomic Medicine Section, CNP/DIR/NINDS/NIH, Bethesda, Maryland (D.G., G.C., P.S.); NIH Academy Enrichment Program, OD/NIH (G.C.); and Sackler Faculty of Medicine, Tel Aviv University, Israel (Y.S.).
National Institutes of Health · USTel Aviv University · IL

Funding

Mechanisms of Parkinson Disease and Related DisordersZ01NS003033 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2007 to 2008
$966k
Intramural NIH HHS Z01 NS003033
6 · The paper itself

Abstract

The endogenous catecholamines dopamine (DA), norepinephrine (NE), and epinephrine (EPI) play key roles in neurobehavioral, cardiovascular, and metabolic processes; various clinical disorders; and effects of numerous drugs. Steps in intracellular catecholamine synthesis and metabolism were delineated long ago, but there remains a knowledge gap. Catecholamines are metabolized by two isoforms of monoamine oxidase (MAO), MAO-A and MAO-B, and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically. MAOs catalyze the conversion of catecholamines to catecholaldehydes-3,4-dihydroxyphenylacetaldehyde (DOPAL) from DA and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from NE and EPI. In this study we exploited the technical ability to assay DOPAL and DOPEGAL simultaneously with the substrate catecholamines to compare DA, NE, and EPI in their metabolism by MAO-A and MAO-B. For both MAO isoforms, DA was the better substrate compared to NE or EPI, which were metabolized equally. Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intraneuronal enzymatic oxidation of catecholamines is via MAO-A. The results have implications for clinical neurochemistry, experimental therapeutics, and computational models of catecholaminergic neurodegeneration. For instance, the greater susceptibility of DA than the other catecholamines to both MAO isoforms can help explain relatively high concentrations of the deaminated DA metabolite 3,4-dihydroxyphenylacetic acid than of the NE metabolite 3,4-dihydroxyphenylglycol in human plasma and urine. SIGNIFICANCE STATEMENT: Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI). Based on measurements of DOPAL and DOPEGAL production, DA is a better substrate than NE or EPI for both MAO isoforms, and MAO-A is more efficient than MAO-B in metabolizing DA, NE, and EPI. MAO-A is the main route of intraneuronal metabolism of endogenous catecholamines.

Indexed as

CatecholaminesDopamineEpinephrineMonoamine OxidaseMonoamine Oxidase InhibitorsNorepinephrineCatecholaminesDopamineEpinephrineMonoamine OxidaseMonoamine Oxidase InhibitorsNorepinephrine

Identifiers

PMID34503991
PMCPMC9164308
OpenAlexW3197941293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.